Timber pharmaceuticals provides business update and announces second quarter 2022 financial results

Timber enrolls first patients in phase 3 ascend clinical trial after receiving breakthrough designation from fda for lead asset tmb-001
TMBR Ratings Summary
TMBR Quant Ranking